ÀÎÇüÀ§¾Ï¼¼Æ÷¿¡¼ Cisplatin ȹµæ³»¼º¿¡ ÀÇÇÑ ¹æ»ç¼±°¨¼ö¼ºÀÇ º¯È
Radiosensitivity in Acquired Cisplatin-Resistant Human Stomach Adenocarcinoma Cells
¹Ú¿ìÀ±, È«¿ø¼±,
¼Ò¼Ó »ó¼¼Á¤º¸
¹Ú¿ìÀ± ( )
Ãæ³²´ëÇб³
È«¿ø¼± ( )
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
KMID : 0360319970290040584
Abstract
¸ñ Àû: cisplatin¿¡ ´ëÇÑ ³»¼ºÈ¹µæÀÌ ¹æ»ç¼±°¨¼ö¼º¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ±Ô¸í
Àç·á ¹× ¹æ¹ý: ÀÎÇüÀ§¾Ï¼¼Æ÷ÁÖÀÎ MKN-45¿Í ÀÌ ¼¼Æ÷·ÎºÎÅÍ À¯µµÇÑ cisplatin ȹµæ³»¼º¼¼
Æ÷ÀÎ MKN/CDDP¸¦ ´ë»óÀ¸·Î cisplatin°ú ¹æ»ç¼±¿¡ ´ëÇÑ °¨¼ö¼ºÀ» °¢°¢ MTT Å×½ºÆ®¿Í ´Ü
ÀÏ Á¶»çÈÄÀÇ Áý¶ôÇü¼º´É·ÂÀ¸·Î ÃøÁ¤ÇÏ¿´´Ù. ¶ÇÇÑ ¹æ»ç¼±°¨¼ö¼ºÀÇ º¯¼ö·Î Do¿Í nÀ» »êÃâÇÏ
¿´´Ù.
°á °ú: MKN-45¿Í MKN/CDDPÀÇ cisplatin¿¡ ´ëÇÑ IC50´Â °¢°¢ 2.28°ú 6.26
¥ìg/ml À̾ú´Ù. MKN-45¿Í MKN/CDDPÀÇ ¹æ»ç¼±¿¡ ´ëÇÑ IC50´Â °¢°¢ 2.10°ú
2.20 Gy À̾ú´Ù. MKN/CDDP´Â IC50·Î Æò°¡ÇÏ¿´À» °æ¿ì ¸ð¼¼Æ÷ÀÎ MKN-45
¿¡ ºñÇÏ¿© cisplatin°ú ¹æ»ç¼±¿¡ ´ëÇÏ¿© °¢°¢ 2.75¿Í 1.05¹èÀÇ ³»¼ºÀ» º¸ÀÌ´Â ¼¼Æ÷À̾ú´Ù.
MKN-45¿Í MKN/CDDP¿¡¼ÀÇ DoÄ¡´Â °¢°¢ 1.11¡¾0.25¿Í 2.63¡¾0.43 Gy, nÄ¡´Â °¢°¢ 1.78¡¾
0.31°ú 1.23¡¾0.30À¸·Î À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾ú´Ù(p>0.05).
°á ·Ð: cisplatin¿¡ ´ëÇÑ È¹µæ³»¼ºÀÌ ¹æ»ç¼±¿¡ ´ëÇÑ ³»¼ºÀ» Ç×»ó ÃÊ·¡ÇÏ´Â °ÍÀº ¾Æ´Ï´Ù.
#ÃÊ·Ï#
INTRODUCTION
Combinations of chemotherapy and radiotherapy have been used under the assumption
of no cross-resistance between chemotherapeutic drugs and ionizing radiation. Previous
clinical trials with induction chemotherapy and subsequent radiotherapy, however, have
frequently shown that the response to radiotherapy was affected by the induction
chemotherapy.
Cisplatin (CDDP) is one of the widely used chemotherapeutic drugs in clinic because
of its broad spectrum of the potent anticancer activity. Although the combined treatment
with CDDP and radiation was reported to have the positive effect on the treatment of
several kinds of human cancers, most of those studies were not controlled studies.
Moreover clinical studies are not frequently suitable to evaluate the precise effect of the
chemotherapy on the subsequent radiotherapy. This study was conducted to investigate
the effect of chemotherapy with CDDP on the subsequent radiotherapy using human
stomach adenocarcinoma cell line and its subline resistant to CDDP.
Å°¿öµå
ÀÎÇüÀ§¾Ï¼¼Æ÷; ȹµæ³»¼º; cisplatin; ¹æ»ç¼±°¨¼ö¼º;
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸